Cited 12 times in
Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤동섭 | - |
dc.contributor.author | 이동기 | - |
dc.contributor.author | 이세준 | - |
dc.contributor.author | 임재윤 | - |
dc.contributor.author | 조재용 | - |
dc.date.accessioned | 2016-02-04T11:12:15Z | - |
dc.date.available | 2016-02-04T11:12:15Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/139897 | - |
dc.description.abstract | PURPOSE: The purpose of this study is to retrospectively compare the efficacy and tolerability between three regimens for first-line chemotherapy-gemcitabine plus capecitabine (GEM-X), gemcitabine plus erlotinib (GEM-T), and gemcitabine monotherapy (GEM)-in patients with advanced pancreatic cancer. MATERIALS AND METHODS: There was a total of 127 patients who underwent chemotherapy for pancreatic cancer between January 2007 and November 2011 at our institution. Patients were treated with either GEM (gemcitabine 1,000 mg/m(2) on days 1, 8, and 15 every 4 weeks), GEM-T (gemcitabine 1,000 mg/m(2) on days 1 and 8 every 3 weeks and erlotinib 100 mg daily), or GEM-X (gemcitabine 1,000 mg/m(2) on days 1 and 8 every 3 weeks and capecitabine 850 mg/m(2) twice daily for 2 weeks followed by 1 week's rest) as the first-line treatment. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and toxicity were evaluated. RESULTS: The patient population was divided into groups depending on their first-line treatment: GEM (n=47), GEM-T (n=44), and GEM-X (n=36). GEM-X significantly improved ORR (21.2% vs. 12.7% and 15.9%), PFS (8.9 vs. 5.2 and 3.9 months; p < 0.001), and OS (12.1 vs. 10.4 and 9.9 months; p = 0.03) compared to GEM and GEM-T, respectively. There were higher incidences of some non-hematologic adverse events with GEM-X and GEM-T compared to GEM, but most were grade 1 or 2. CONCLUSION: GEM-X presented better clinical efficacy and acceptable tolerability than GEM-T and GEM in advanced pancreatic cancers. It is worthy to further investigate which agent has a clinical advantage as a combination drug with gemcitabine in pancreatic cancer and to explore the predictive markers leading to personalize anti-cancer treatment. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 266~273 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Jae Yun Lim | - |
dc.contributor.googleauthor | Jang Ho Cho | - |
dc.contributor.googleauthor | Se Joon Lee | - |
dc.contributor.googleauthor | Dong Ki Lee | - |
dc.contributor.googleauthor | Dong Sup Yoon | - |
dc.contributor.googleauthor | Jae Yong Cho | - |
dc.identifier.doi | 10.4143/crt.2013.158 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02548 | - |
dc.contributor.localId | A02723 | - |
dc.contributor.localId | A02882 | - |
dc.contributor.localId | A03398 | - |
dc.contributor.localId | A03899 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 25327494 | - |
dc.subject.keyword | Capecitabine | - |
dc.subject.keyword | Drug therapy | - |
dc.subject.keyword | Erlotinib | - |
dc.subject.keyword | Gemcitabine | - |
dc.subject.keyword | Pancreatic neoplasms | - |
dc.contributor.alternativeName | Yoon, Dong Sup | - |
dc.contributor.alternativeName | Lee, Dong Ki | - |
dc.contributor.alternativeName | Lee, Se Joon | - |
dc.contributor.alternativeName | Lim, Jae Yun | - |
dc.contributor.alternativeName | Cho, Jae Yong | - |
dc.contributor.affiliatedAuthor | Yoon, Dong Sup | - |
dc.contributor.affiliatedAuthor | Lee, Dong Ki | - |
dc.contributor.affiliatedAuthor | Lee, Se Joon | - |
dc.contributor.affiliatedAuthor | Lim, Jae Yun | - |
dc.contributor.affiliatedAuthor | Cho, Jae Yong | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 47 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 266 | - |
dc.citation.endPage | 273 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.47(2) : 266-273, 2015 | - |
dc.identifier.rimsid | 48363 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.